Robert G Holloway, Ira Shoulson, Stanley Fahn, Karl Kieburtz, Anthony Lang, Kenneth Marek, Michael McDermott, John Seibyl, William Weiner, Bruno Musch, Cornelia Kamp, Mickie Welsh, Aileen Shinaman, Rajesh Pahwa, Lynn Barclay, Jean Hubble, Peter LeWitt, Janis Miyasaki, Oksana Suchowersky, Mark Stacy, David S Russell, Blair Ford, John Hammerstad, David Riley, David Standaert, Frederick Wooten, Stewart Factor, Joseph Jankovic, Farah Atassi, Roger Kurlan, Michel Panisset, Ali Rajput, Robert Rodnitzky, Cliff Shults, Giselle Petsinger, Cheryl Waters, Ronald Pfeiffer, Kevin Biglan, Leona Borchert, Amy Montgomery, Laura Sutherland, Carolyn Weeks, Maryan DeAngelis, Elspeth Sime, Susan Wood, Carol Pantella, Mary Harrigan, Barbara Fussell, Sandra Dillon, Barbara Alexander-Brown, Pamela Rainey, Marsha Tennis, Elke Rost-Ruffner, Diane Brown, Sharon Evans, Debra Berry, Jean Hall, Theresa Shirley, Judith Dobson, Deborah Fontaine, Brenda Pfeiffer, Alicia Brocht, Susan Bennett, Susan Daigneault, Karen Hodgeman, Carolynn O'Connell, Tori Ross, Karen Richard, Arthur Watts
BACKGROUND: The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear. OBJECTIVE: To compare initial treatment with pramipexole vs levodopa in early Parkinson disease, followed by levodopa supplementation, with respect to the development of dopaminergic motor complications, other adverse events, and functional and quality-of-life outcomes. DESIGN: Multicenter, parallel-group, double-blind, randomized controlled trial...
July 2004: Archives of Neurology